APP下载

舍曲林联合尼莫地平治疗脑卒中后抑郁疗效观察

2014-09-12谈鹰钮富荣

中国现代医生 2014年18期

谈鹰++钮富荣

[摘要] 目的 探讨舍曲林联合尼莫地平治疗脑卒中后抑郁的疗效。方法 选取我院2011年1月~2013年1月确诊的60例脑卒中后抑郁患者作为研究对象,随机分为观察组与对照组,每组30例,两组均予营养脑细胞药物,其中对照组予舍曲林50~100 mg,晨顿服,观察组同时加用尼莫地平30 mg/次,每日3次,舍曲林50~100 mg,晨顿服。疗程8周。对比分析两组患者治疗前后HAMD-17评分、临床疗效、不良反应情况。结果 两组治疗前HAMD-17评分差异无统计学意义(P >0.05), 治疗2周后,两组的HAMD-17评分均较治疗前明显降低,差异具有统计学意义(P<0.05)。治疗4周后,两组的HAMD-17评分均较治疗前及治疗2周后明显降低,差异具有统计学意义(P<0.05)。治疗6周后,两组的HAMD-17评分均较治疗前及治疗2周后、治疗4周后明显降低,差异具有统计学意义(P<0.05)。观察组治疗后无效2例,总有效率93.33%,对照组的总有效率70.00%,两组疗效比较,差异具有统计学意义(P<0.05),观察组治疗期间无一例出现食欲减退、口干、皮疹,其并发症发生率10%,对照组并发症发生率达40.00%,两组不良反应比较,差异具有统计学意义(P<0.05)。 结论 舍曲林联合尼莫地平治疗脑卒中后抑郁疗效确切,且安全性好,值得推广和应用。

[关键词] 脑卒中后抑郁;舍曲林;尼莫地平

[中图分类号] R749.1[文献标识码] B[文章编号] 1673-9701(2014)18-0048-03

Effects observed after treatment of stroke depression sertraline nimodipine

TAN Ying1 NIU Furong2

1.Department of Neurology, Huzhou City Central Hospital in Zhejiang Province, Huzhou313000, China ; 2. Department of Psychiatric, Huzhou City Central Hospital in Zhejiang Province, Huzhou313000,China

[Abstract] Objective To investigate the efficacy of sertraline and nimodipine in treatment of stroke depression. MethodsSelecteddiagnosed post-stroke depression in our hospital from January 2011 to January 2013 as observed object. 60 cases of stroke depression were randomly divided into observation group and control group of 30 patients, were treated nutrition brain cells, the control group received sertraline 50~100 mg,observation group added in the nimodipine 30 mg / time, 3 times a day, sertraline 50~100mg, the course were 8 weeks. Before and after treatment, HAMD-17 score, the clinical efficacy of adverse reactions after treatment were compared betweentwo groups. ResultsBefore treatment, differences HAMD-17 score of were not statistically significant(P> 0.05), After 2 weeks of treatment, HAMD-17 score the observation group and control group of was significantly lower than before treatment,(P<0.05). After 4 weeks of treatment, HAMD-17 score of the observation group and control group was significantly lower than before treatment and after 2 weeks of treatment,the difference was significant(P <0.05). After 6 weeks of treatment , the HAMD-17 observation group and control group score reducedthan before treatment and after 2 weeks of treatment , reduced significantly than after 4 weeks of treatment, the difference was significant(P <0.05). Total efficiency of observation group was 93.33%, the total efficiency of the control group was 70.00%, the difference of the effect was significant between two groups(P < 0.05). No case occurred during the observation group therapy anorexia, dry mouth , rash , and its complication rate of 10 % of the observation group , the control group complication rate of 40.00%, the difference was significant between two groups(P < 0.05). Conclusion Sertraline and nimodipine treatment stroke depression has good efficacy, and safety, and it is worthy of promotion and application.

[Key words] Poststroke depression; Sertraline; Nimodipine

脑卒中后抑郁(post-stroke depression,PSD)占脑卒中的20%~60%,多发生在脑卒中3个月内[1]。脑卒中后抑郁的临床表现主要为抑郁心境的情感障碍,严重影响患者的神经功能和日常生活能力,因此,应重视对脑卒中后抑郁患者的预防和治疗。目前临床对于抑郁症患者多给予抗抑郁药物治疗,其中舍曲林属于新型选择性5-HT再摄取抑制剂,可阻断神经细胞突触前膜对5-HT的再摄取,使突触间隙内5-HT增多,从而发挥抗抑郁作用[2]。尼莫地平是钙离子拈抗剂,可明显改善脑卒中患者的认知功能[3],但其对卒中后抑郁的疗效报道不多,本研究旨在探讨舍曲林联合尼莫地平治疗脑卒中后抑郁的疗效,现报道如下。

1对象与方法

1.1研究对象

选取我院2011年1月~2013年1月期间确诊的脑卒中后抑郁患者60例作为研究对象,均首次发病, 经颅脑CT或MRI确诊,均符合《中国精神障碍分类与诊断标准(第3版)》中器质性精神障碍抑郁状态的诊断标准和1995年全国第4届脑血管病会议通过的《各类脑血管疾病诊断要点》,即汉密尔顿抑郁量表(HAMD)17项不低于18分; ……

登录APP查看全文